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Understanding the patient journey to
diagnosis of lung cancer
Yichen Zhang1, Michael J. Simoff2*, David Ost3, Oliver J. Wagner4, James Lavin4, Beth Nauman5, Mei-Chin Hsieh6,
Xiao-Cheng Wu6, Brian Pettiford7 and Lizheng Shi1

Abstract
Objective: This research describes the clinical pathway and characteristics of two cohorts of patients. The first
cohort consists of patients with a confirmed diagnosis of lung cancer while the second consists of patients with a
solitary pulmonary nodule (SPN) and no evidence of lung cancer. Linked data from an electronic medical record
and the Louisiana Tumor Registry were used in this investigation.
Materials and methods: REACHnet is one of 9 clinical research networks (CRNs) in PCORnet®, the National PatientCentered Clinical Research Network and includes electronic health records for over 8 million patients from multiple
partner health systems. Data from Ochsner Health System and Tulane Medical Center were linked to Louisiana
Tumor Registry (LTR), a statewide population-based cancer registry, for analysis of patient’s clinical pathways
between July 2013 and 2017. Patient characteristics and health services utilization rates by cancer stage were
reported as frequency distributions. The Kaplan-Meier product limit method was used to estimate the time from
index date to diagnosis by stage in lung cancer cohort.
Results: A total of 30,559 potentially eligible patients were identified and 2929 (9.58%) had primary lung cancer. Of
these, 1496 (51.1%) were documented in LTR and their clinical pathway to diagnosis was further studied. Time to
diagnosis varied significantly by cancer stage. A total of 24,140 patients with an SPN were identified in REACHnet and
15,978 (66.6%) had documented follow up care for 1 year. 1612 (10%) had no evidence of any work up for their SPN.
The remaining 14,366 had some evidence of follow up, primarily office visits and additional chest imaging.
Conclusion: In both cohorts multiple biopsies were evident in the clinical pathway. Despite clinical workup, 70% of
patients in the lung cancer cohort had stage III or IV disease. In the SPN cohort, only 66% were identified as receiving a
diagnostic work-up.
Keywords: Lung cancer, Clinical pathway, Bronchoscopy, Pulmonary nodule, Biopsy frequency, Staging

Background
Lung cancer is the leading cause of cancer-related deaths
in the United States, causing more deaths than colorectal, breast, and prostate cancers combined [1]. An estimated 135,720 Americans are expected to die of lung
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cancer in 2020, accounting for about 22% of all cancer
deaths in the United States [1]. The 5-year relative survival rate for patients with lung cancer is poor and varies
considerably from 59% for patients with localized disease, 31.7% for patients with regional disease, and 5.8%
for people with distant disease. The relative 5-year survival for those with stage unknown is 8.3% [2]. Trends in
relative survival have improved slightly from 12.5% in
1975–1979 to 19.9%% in 2012 attributable to changes in
smoking patterns and therapeutic improvements [1].
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Routine screening for lung cancer has not yet been
broadly adopted despite evidence that screening high
risk patients (i.e., 30 pack years of cigarette smoking)
with the use of low-dose CT reduces mortality from
lung cancer [3, 4]. Engaging primary care clinicians and
garnering support from payors to ensure routine lung
cancer screening adoption will have a significant impact
on overall patient survival [5]. Currently, most lung cancer (84%) is diagnosed with regional or distant extension
of the disease, limiting treatment options and reducing
relative survival [2].
Patients with lung cancer may follow a variety of
routes within the health-care system. Traditionally, consultation and management have been achieved with referrals to specialists occurring in a sequential fashion.
Symptoms prompt a physician visit, followed by a referral to a specialist culminating in a diagnosis and treatment. This process may be slow, and delays are
common. Asymptomatic patients with a solitary pulmonary nodule may suffer even longer delays as the
guidelines recommend watchful waiting rather than
more aggressive diagnostic procedures especially for
those nodules < 8 mm [6]. Previous studies of diagnostic
delay in lung cancer (i.e., abnormal chest imaging to
diagnosis) have shown a median delay between 25 and
53 days [7–9] but delays have been shown to be skewed
with some patients having much longer delays [9, 10].
Currently, lung cancer diagnosis and staging have increased in complexity due to an expanding number of
options such as PET imaging, endobronchial ultrasound,
as well as navigational and robotic bronchoscopy. These
tools allow for more extensive tissue sampling and accurate diagnosis and staging. Patients with early-stage
disease are often eligible for potentially curative therapy
with minimally invasive surgery and advanced radiotherapy techniques. For patients with more advanced disease, molecular profiling for tumor mutations may guide
the use of targeted therapies such as ALK, BRAF, ROS1,
RET, NTRK, MET (with EGFR inhibitors) and anti PD1/PD-L1 immune checkpoint inhibitors [11]. Such molecular analysis may require additional tissue sampling
or sample analysis at a remote specialty lab. These factors, among others in the patient journey, indicate there
is no singular pathway to a diagnosis of lung cancer and
add to the variability of timely diagnosis [12–15].
We conducted a retrospective cohort study using data
from the electronic health records of Tulane Medical
Center and Ochsner Health System linked to the Louisiana Tumor Registry to document the patient pathway to
lung cancer diagnosis and report the pattern of procedures and physician visits. For patients with lung nodules ultimately diagnosed as malignant we report the
median time to diagnosis. For patients with lung nodules
diagnosed as benign, we report on diagnostic lung
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procedures performed during the subsequent 1-year
from nodule identification.

Methods
This is a retrospective cohort study, using linked data information systems, designed to document the patient
pathway from (a) identification of a pulmonary nodule
to lung cancer diagnosis, and (b) identification of a pulmonary nodule to 1-year follow-up among those with no
lung cancer diagnosis.
Datasets

The Louisiana Tumor Registry (LTR) is a populationbased cancer registry that is authorized by law to collect
data on cancer diagnosis, treatment, and survival from
all healthcare facilities and providers. The LTR is a participant of the NCI’s Surveillance, Epidemiology, and
End Result Program and the CDC’s National Program of
Cancer Registries. The LTR’s data have met the data
completeness, timeliness, and quality standards for both
SEER and NPCR programs and the North American Association of Central Cancer Registries [16].
The Research Action for Health Network (REACHnet)
is a partnership of health systems, academic centers, and
public health organizations that constitute an innovative
data network for conducting multi-site research with enhanced efficiency in real-world healthcare delivery systems. With national and local collaborators, REACHnet
implements research that addresses healthcare questions
of critical importance to patients and clinicians and contributes to the evidence base that will inform more effective healthcare decision-making and improve
population health. The network includes clinical records
for more than 8 million patients across multiple partner
health systems located in Louisiana, Texas, and California. For the current study, data were obtained through
REACHnet (https://reachnet.org/) for qualifying patients
receiving care at Ochsner Health System and Tulane
Medical Center in Louisiana.
Data linkage

Data linkage between these two information systems was
performed using a Global Patient Identification (GPID),
provided by REACHnet. A software application, Distributed Common Identity for the Integration of Regional
Health Data (DCIFIRHD), was used to perform secure,
cross-site aggregation and linkage of patient records between LTR and REACHnet. Patient identification information (e.g., first name, last name, date of birth, SSN,
gender), was hashed in various combinations with a sitespecific password and a shared seed to create up to 17
hashes for each patient. These Seeded Hash Identifiers
(HashIDs) were sent to an honest broker site, REAC
Hnet, where the hashed output was merged using a
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deterministic algorithm that applied sets of rules to the
Seeded HashIDs of common patient identifiers to identify matches between records. Two records from REAC
Hnet and LTR with the same Seeded HashID were considered a “match” (i.e., be the same patient) if they had
the same value for certain Seeded HashIDs. Unique
study IDs were then used to replace the matched
HashIDs [16]. A primary lung cancer diagnosis in REAC
Hnet was identified using ICD-9-CM (International
Classification of Diseases, Ninth Revision, Clinical Modification) and ICD-10-CM (International Classification of
Diseases, Tenth Revision, Clinical Modification) diagnosis codes. Patients with primary lung cancer diagnosis in
LTR were identified using ICD-O-3 (International Classification of Diseases for Oncology, Third Revision)
codes C340-C349.

Study population

Our goal was to identify all patients in Tulane and Ochsner healthcare systems who had either a malignant or
benign lung nodule between 2013 and 2019. Figure 1
shows the patient selection process and the resulting
study populations. Patients with (a) a qualifying biopsy
defined by Current Procedural Terminology (CPT) codes
or (b) a diagnosis of Suspicious Pulmonary Nodule
(SPN) or (c) Low-Dose Computed Tomography (LDCT)
defined by ICD-9 or ICD-10 codes in REACHnet between 2013 and 2019 were identified and the first recorded date of SPN or LDCT or chest imaging was
defined as the index date (see Appendix 1 for code lists).

Fig. 1 Sample selection flow chart
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Patients were excluded from further assessment if (a)
they had a Biopsy only N = 972 (2.74%), (b) they had a
SPN with pleural biopsy as first biopsy N = 903 (2.55%),
(c) their index date occurred prior to 1/7/2013 N = 2181
(6.15%), (d) their index date was after 12/31/2017 N = 70
(0.20%) (linkage to LTR was not available after 12/31/
17), (e) their diagnosis with primary lung cancer diagnosis in REACHnet occurred in 2018–2019 N = 196
(0.55%), (f) lung cancer was a secondary diagnosis N =
527 (1.49%), (g) they were not Louisiana residents N = 3
(0.01%), (h) they were diagnosed through Death Certificate only (DCO) N = 25 (0.07%) and (i) they were diagnosed with lung cancer only at autopsy N = 1 (0.003%).
A total of 4878 patients met these exclusion criteria and
were eliminated from further study. (See Fig. 1) A total
of 30,559 patients from REACHnet were linked to the
LTR including 2929 patients with a primary lung cancer
diagnosis in REACHnet and 27,630 patients without a
lung cancer diagnosis in REACHnet between 2013 and
2017. Of the 2929 patients with a lung cancer diagnosis
in REACHnet, 1496 had a primary lung cancer diagnosis
in both the Tulane or Ochsner health care systems and
in the LTR. These 1496 subjects constitute the lung cancer patient population. Records for these 1496 patients
were assembled to document patient care from index
date to diagnosis date. The diagnosis date from the LTR
was used as the study endpoint for the lung cancer cohort and was defined using the earliest date of cytology,
or biopsy, or staging biopsy date in the LTR. If none of
these dates were available, then the diagnosis date as recorded in the LTR was used.
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Of the 27,630 patients without a lung cancer diagnosis
in REACHnet between 2013 and 2017, 3490 had no evidence of SPN at baseline (i.e., qualified for study inclusion based on a biopsy or LDCT) or during the 1 year of
follow-up. In addition, a total of 150 patients had evidence of lung cancer following data linkage with LTR,
presumably having left Tulane or Ochsner healthcare
systems to receive care elsewhere. Of the remaining 23,
990 patients with SPN at baseline or during the 1-year
follow-up, a total of 15,978 had continuous enrollment
in REACHnet during the 1-year follow-up period and no
evidence of a lung cancer diagnosis. These subjects constitute the SPN patient population. The medical records
for these 15,978 patients were assembled to document
care from the first recorded SPN (index date) to 1 year
from the initial SPN diagnosis date.

Patient pathway

Utilization of invasive and non-invasive procedures
until diagnosis in the lung cancer cohort and during
the first year following SPN diagnosis in REACHnet
were extracted using ICD-9-CM procedure codes,
ICD-10-CM procedure codes, and Current Procedural
Terminology (CPT) codes. Procedures under investigation in this study included Evaluation and Monitoring (E&M), Biopsy (i.e., surgical biopsy, CT guided
biopsy, and bronchoscopy biopsy), Positron Emission
Tomography-Computed Tomography (PET CT), Brain
Magnetic Resonance Imaging (MRI), and Bone Scan
(Appendix 1).
Biopsy associated complications including pneumothorax, pneumothorax requiring a chest tube, hemorrhage,
and air leak were extracted using ICD-9-CM diagnosis
codes, ICD-10-CM diagnosis codes, CPT procedure codes,
ICD-9-CM procedure codes, and ICD-10-CM procedure
codes (Appendix 1).

Statistical analysis

Descriptive analysis for demographic characteristics was
performed. Demographic characteristics for patients
with lung cancer were compiled from data from the LTR
data, while data for patients with SPN diagnoses without
lung cancer were compiled from REACHnet’s electronic
health record (EHR) data. Continuous variables were reported in mean and standard deviation (SD). Categorical
variables were reported in frequency and percentage distribution. Health services utilization rates were reported
in frequency and percentage distribution. Time from
index date to diagnosis date by stage was analyzed using
the Kaplan-Meier product limit method. All analyses
were performed in SAS 9.4 (SAS Institute, Cary, North
Carolina, USA).
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Results
Table 1 shows selected demographics by patient cohort.
While direct comparisons between cohorts are problematic given the differences in selection criteria and followup, patients in the lung cancer cohort were older with a
preponderance of men relative to patients in the SPN
cohort. As would be expected, patients in the lung cancer cohort had, on average, more invasive procedures
relative to the SPN cohort however patients in the SPN
cohort had more non-invasive procedures relative to the
lung cancer cohort attributable, in part, to the longer
observation period for patients in the SPN cohort.
Table 2 shows the staging and clinical measurements
for lung cancer patients (n = 1496) from index date until
date of diagnosis stratified by subsequent clinic visit.
(Test utilization stratified by stage can be seen in the
online appendix). Approximately 15% of lung cancer patients received a diagnosis of lung cancer on their index
date while only 8% had biopsy information on their
index date. Reasons for the lack of concordance between
diagnosis and biopsy information is unknown but likely
attributable to patients receiving their index scan and/or
biopsy outside of the REACHnet system. The most common clinical measures recorded at this time point were
a chest x-ray and an E&M. The presence of other clinical measurements in the medical record was very low.
Sixty-nine percent of the patients diagnosed on the
index date were Stage 3 or 4. Subsequent visits showed a
similar pattern. For example, at visit 1 following the
index date, 18% received a diagnosis of lung cancer and
76.6% of these patients were stage 3 or 4. The clinical
measurements at visit 1 following the index date showed
a decrease in the frequency of chest imaging and
increases in the frequency of E&M and biopsy. The
frequency of EBUS, PET CT, Brain MRI, and bone scan
also increased although the frequency of these measurements was still low (0.6–3.0%). Approximately 38% of all
lung cancer patients (N = 564) received their diagnosis
on or after the fourth visit. Sixty-three percent of these
individuals were stage 3 or 4. Chest imaging and biopsy
were the most frequently recorded clinical measures
followed by E&M, PET CT and EBUS. The use of LDCT,
brain MRI, and bone scan was infrequent throughout
the patient visitation process.
Figure 2 shows the cumulative probability of diagnosis
for lung cancer patients stratified by AJCC stage.
Approximately 80% of all stage 3 and 4 lung cancer was
diagnosed within a 45-day time period from index date.
Eighty percent of stage 2 lung cancers were diagnosed
within a period of 60 days and 80% of stage 1 cancers
were diagnosed within a period of 90 days. The median
time to diagnosis for all lung cancer patients was 13 days
with an interquartile range of 2 to 46 days and varied
significantly by cancer stage. Approximately 50% of lung
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Table 1 Selected demographic characteristics by cohort
Patients with w/EMR at Tulane and Ochsner and have
confirmed diagnosis in LA tumor registry (N = 1496)

Patients without primary lung cancer
with SPN and 1-year follow up (N = 15,
978)

68.41 (10.03)

61.74 (15.19)

18–34 years old

4 (0.27)

958 (6.00)

35–44 years old

14 (0.94)

1186 (7.42)

45–54 years old

100 (6.68)

2351 (14.71)

55–64 years old

382 (25.53)

4138 (25.90)

≥ 65 years old

996 (66.58)

7345 (45.97)

Male

843 (56.35)

7139 (44.68)

Female

651 (43.52)

8839 (55.32)

White

976 (65.24)

10,461 (65.47)

Black

504 (33.69)

5225 (32.70)

a

16 (1.07)

292 (1.83)

Outside New Orleans

258 (17.25)

n/a

New Orleans Area

1237 (82.69)

Age, mean (SD)
Age group, N (%)

Gender, N (%)

Race, N (%)

Other

Region, N (%)

Health insurance type at diagnosis, N (%)
Medicare

1010 (67.51)

Private Insurance

235 (15.71)

Medicaid

92 (6.15)

Insurance not specified

76 (5.08)

TRICARE/Veterans Affairs

49 (3.28)

Not insured

24 (1.60)

Insurance status unknown

10 (0.67)

n/a

Year of diagnosis, N (%)
2013

165 (11.03)

2014

312 (20.86)

2015

317 (21.19)

2016

347 (23.20)

2017

355 (23.73)

n/a

AJCC stage, N (%)
Stage 0

9 (0.60)

Stage I

308 (20.59)

Stage II

108 (7.22)

Stage III

327 (21.86)

Stage IV

707 (47.26)

Unknown, not staged

37 (2.47)

n/a

Overall:
Average number of invasive proceduresb from index date
to diagnosis date or end of study periodc, mean (SD)

2.11 (0.75)

5.88 (7.68)
Average number of non-invasive procedures from index
date to diagnosis date or end of study periodc, mean (SD)
a

1.58 (1.66)
10.47 (9.68)

Asian, American Indian, Aleutian, or Eskimo
biopsies, EBUS and Mediastinoscopy
Observation periods for each population are different. In the Lung cancer population, index date to diagnosis date. In the SPN population, the index date to the
end of 1 year follow up period
All imaging (cpt 71,250, 71,260, 71,270, 71,010, 71,020, 74,176, 74,178, GO297, GO296, S8032)
All consultations/office visits (99201–99,205, 99,213–99,215, 99,221–99,223, 99,251–99,254)
b
c
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Table 2 Staging and clinical measurements for lung cancer patients from index date by subsequent clinic visit
Visit Characteristics

Patients with confirmed
diagnosis of lung cancer, Index
Date

Visit one
following index
visit

Visit two
following index
visit

Visit three
following index
visit

Visit 4 + all visits up to
end of study period

N = 1496

N = 1275

N = 1002

N = 752

N = 564

Days (median (IQR))
between visits

4 (1,11)

5 (1,12)

5 (1,12)

6.5 (1,25)

Cumulative days from
index visit (median (IQR))

4 (1,11)

11 (4,25)

20 (8, 51)

48 (16, 268)

3 (0.24)

1 (0.10)

0 (0.00)

2 (0.35)

LDCT scan

9 (0.60)

Chest Imaging

1085 (72.53)

434 (34.04)

331 (33.03)

263 (34.97)

443 (78.55)

E&M

577 (38.57)

675 (52.94)

446 (44.51)

338 (44.95)

379 (67.20)

EBUS/mediastinoscopy

29 (1.94)

42 (3.29)

34 (3.39)

33 (4.39)

106 (18.79)

Biopsya

116 (7.75)

252 (19.76)

250 (24.95)

183 (24.34)

439 (77.84)

PET CT

20 (1.34)

47 (3.69)

69 (6.89)

44 (5.85)

119 (21.10)

Brain MRI

45 (3.01)

33 (2.59)

27 (2.69)

10 (1.33)

44 (7.80)

Bone scan

4 (0.27)

8 (0.63)

6 (0.60)

5 (0.66)

7 (1.24)

SPN diagnosis

1066 (71.26)

786 (61.65)

625 (62.38)

462 (61.44)

515 (91.31)

Lung cancer diagnosis
madeb

221 (14.77)

273 (18.24)

250 (16.71)

188 (12.57)

564 (37.70)

Stage I

38 (17.19)

47 (17.22)

41 (16.40)

35 (18.62)

147 (26.06)

Stage II

20 (9.05)

13 (4.76)

24 (9.60)

14 (7.45)

37 (6.56)

Stage III

39 (17.64)

53 (19.41)

56 (22.40)

52 (27.66)

127 (22.52)

Stage IV

114 (51.58)

156 (57.14)

124 (49.60)

81 (43.09)

232 (41.13)

Unknown, not staged

10 (4.52)

4 (1.47)

4 (1.60)

6 (3.19)

13 (2.30)

AJCC Stage at diagnosis
1 (0.40)

Stage 0

8 (1.42)

a

all biopsy types from REACHnet database. Excludes EBUS/Mediastinoscopy (counted separately) and biopsy of the pleura
% relative to the total number of cancer patients (N = 1496)

b

cancer patients were diagnosed as stage 4 with a median
time to diagnosis of 7 days while stage 3 (22% of the
population), stage 2 (7% of the population), and stage 1
(21% of the population) patients’ median times to diagnosis were 16, 16.5 and 33 days respectively. (data not
shown). The time from index date to diagnosis was significantly shorter for those with stage 3 or 4 lung cancer
compared to those diagnosed at an earlier stage (Log
rank test, p < 0.0001). Despite the differences in time to
diagnosis by lung cancer stage, the tests and procedures
on the index date and by visit subsequent to index date
are remarkably comparable (see supplemental Table).
For example, chest imaging on index date was 67, 68, 73
and 78% for stages 1–4 respectively while biopsy on the
index date was 7.6, 13.0, 7.7 and 6.7% respectively.
The pattern of clinical measurements on index date
and subsequent visits from index for SPN patients is
shown in Table 3. A total of 15,978 patients received a
SPN diagnosis and were followed for 1 year to determine
subsequent work up characteristics. Ten percent of this
population (n = 1612) had no evidence of a SPN workup following the index SPN diagnosis. The remaining

14,366 (89.9%) had some evidence of an SPN workup in
their medical record the majority of which was E&M
and additional chest imaging. Among this group, the recording of LDCT, EBUS, or bone scan was infrequent
(< 1%) while the use of biopsy, PET CT and brain MRI
ranged from 3 to 6%. Approximately 65% of this patient
cohort was seen 4 or more times during the follow-up
period and this group tended to have more procedures
and documentation of SPN workup compared to those
with 3 or fewer visits.
Table 4 shows the distribution of biopsies by type, frequency and cohort (lung cancer, SPN only). A total of
1167 (79.4%) lung cancer patients had biopsy information in their EHR, 48.3% of which were bronchoscopic, 42.8% CT guided and 8.9% surgical. A total
of 25.7% had multiple biopsies and the average number of biopsies was 1.25 per patient. A total of 932
(5.83%) of SPN patients had biopsy information,
either from their index visit or during follow-up in
their EHR, 69.1% of which were bronchoscopic,
19.3% CT guided and 11.6% surgical. A total of
35.5% of these patients had multiple biopsies and

Zhang et al. BMC Cancer

(2021) 21:402

Page 7 of 11

Fig. 2 Cumulative probability of diagnosis for lung cancer patients, stratified by AJCC stage (stage I - stage IV)

the average number of biopsies was approximately
1.36 per patient.
The overall complication rates following biopsy procedures was low in both cohorts; 3.2% in the lung cancer
cohort and 2.68% in the SPN cohort. (Appendix 2)
Pneumothorax following CT guided biopsy was the most
common complication reported in 4.3 and 5.2% of lung
cancer and SPN patients respectively.

Discussion
Numerous studies have documented the timeliness of
diagnosis and treatment of lung cancer patients, the majority of which come from European Union member
countries. In a systematic review of the literature, Olsson
et al. identified 49 studies in which at least one timeinterval in lung cancer care was reported [17]. Median
times to diagnosis ranged from 8 to 60 days dependent
upon the starting point in the patient journey; some

studies began at the identification of symptoms while
others started at the identification of a SPN on x-ray or
CT. The US studies included in this systematic review
were three, small, single center VA hospital chart reviews that reported a median time from CT to diagnosis
of 45 days [18] and median times from “consultation” to
surgery of 82 days and 104 days [19, 20]. More recently,
Miaga et al. conducted a chart review of 265 veterans
who underwent cancer resection from 2005 to 2015 to
assess time intervals between nodule identification, diagnosis, and surgical resection; changes in nodule radiographic size over time; final pathologic staging; and
reasons for delays in care [21]. They reported a median
time from nodule identification to resection of 98 days
with an interquartile range of 66–139 days. Yorio and
colleagues identified 482 lung cancer patients treated at
three hospitals associated with the University of Texas
(UT) Southwestern Medical Center and reported a
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Table 3 Clinical measurements for SPN patients from index date by subsequent clinic visit
Visit Characteristics

Patients with SPN and no
diagnosis of Lung Cancer

Visit one
following index
visit

Visit two
following index
visit

Visit three
following index
visit

Visit 4 + all visits up to
end of study period

N = 15,978

N = 14,366

N = 13,009

N = 11,715

N = 10,476

Days (median (IQR))
between visits

11 (3, 42)

16 (4, 50)

17 (5, 49)

32.5 (19.3, 56.1)

Cumulative days from
index visit (median (IQR))

11 (3, 42)

38 (12, 104)

67 (25, 151)

196.4 (148.6, 251.5)

LDCT scan

26 (0.16)

4 (0.03)

3 (0.02)

3 (0.03)

6 (0.06)

Chest Imaging

9874 (61.80)

4868 (33.89)

3623 (27.85)

2931 (25.02)

5717 (54.57)

E&M

6129 (38.36)

9632 (67.05)

9483 (72.90)

8886 (75.85)

9972 (95.19)

EBUS/mediastinoscopy

28 (0.18)

34 (0.24)

23 (0.18)

25 (0.21)

75 (0.72)

Biopsya

187 (1.17)

157 (1.09)

143 (1.10)

96 (0.82)

399 (3.81)

PET CT

99 (0.62)

101 (0.70)

100 (0.77)

62 (0.53)

284 (2.71)

Brain MRI

104 (0.65)

148 (1.03)

107 (0.82)

95 (0.81)

576 (5.50)

Bone scan

7 (0.04)

12 (0.08)

21 (0.16)

15 (0.13)

77 (0.74)

SPN diagnosis

15,978 (100.00)

3597 (25.04)

2432 (18.69)

1818 (15.52)

3558 (33.96)

1612 (10.09)

1357 (8.49)

1294 (8.10)

1239 (7.75)

b

Loss to follow up, N (%)
a

biopsies do not include EBUS/mediastinoscopy
b
% relative to the total number of cancer patients (N = 15,978)

median of 16 days from image to diagnosis with an interquartile range of 6–43 days [22]. Nadpara et al. used National
Cancer
Institute’s
(NCI)
Surveillance,
Epidemiology, and End Results (SEER)-Medicare linked
data files from years 2002–2007 and reported a median
of 187 days with an interquartile range of 36–308 days
from first recorded symptoms to diagnosis [23]. The difficulty in using first recorded symptoms as the starting
point in a patient journey is their lack of specificity.
Cough, shortness of breath and chest pain were the most
frequently reported symptoms prior to diagnosis in a
Canadian study of lung cancer patients; symptoms common to a variety of disease states from asthma to cardiac
disease [24]. Our study focused on the time period from

first identified SPN, CT image or qualifying biopsy to
diagnosis and found a median of 13 days with an interquartile range of 2 to 46 days. However, we found that
there are significant differences in the timeliness of diagnosis by cancer stage; stage 3 and 4 cancers being diagnosed more quickly than stage 1 or 2 cancers. In
addition, there is a great deal of dispersion irrespective
of clinical stage with some 5–20% of patients requiring
more than 6 months to get a diagnosis.
While guidelines exist regarding the evaluation of individuals with pulmonary nodules and lung cancer there
are few guidance documents recommending timelines
for lung nodule identification to diagnosis [6, 25, 26].
The NHS has recently published a handbook

Table 4 Patients with record of Biopsy by typea
CT guided biopsy

Bronchoscopy

Surgical biopsy

Total procedures

Unique # of patients

lung cancer SPN
DX
only

lung cancer SPN
DX
only

lung cancer SPN
DX
only

lung cancer SPN
DX
only

lung cancer SPN
DX
only

Total number of
procedures, N (%)

628 (42.75)

271
(19.32)

710 (48.33)

970
(69.14)

131 (8.92)

162
(11.55)

1469

1403

1167
(100.00)

932
(100.00)

1st biopsy

500 (42.84)

231
(24.79)

637 (54.58)

618
(66.31)

30 (2.57)

83
(8.91)

1167

932

1167
(100.00)

932
(100.00)

2nd biopsy

110 (42.97)

33
(16.18)

65 (25.39)

114
(55.88)

81 (31.64)

57
(27.94)

256

204

256 (21.94)

204
(21.89)

3rd biopsy

15 (39.47)

7 (8.64)

7 (18.42)

59
(72.84)

16 (42.11)

15
(18.52)

38

81

38 (3.26)

81 (8.69)

> 4 or more biopsy

3 (37.50)

0 (0.00)

1 (12.50)

179
(96.24)

4 (50.00)

7 (3.76)

8

186

6 (0.51)

46 (4.94)

a

from REACHnet database. Bronchoscopy includes EBUS. Surgical includes mediastinoscopy. Pleural biopsy excluded
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recommending that the time from nodule identification
to diagnosis should be no more than 28 days [27]. Similar recommendations come from Canada and Norway
[28, 29]In this study, approximately 75–80% of patients
with stage 3 or 4 cancer were diagnosed within a 30-day
period from nodule identification. The timeliness of
diagnosis for those with stage 1 or 2 lung cancer was less
with approximately 55–65% receiving a diagnosis within
30 days of nodule identification. These differences in
timeliness of diagnosis by stage were statistically significant at the p < 0.001 level. This could be attributable to
symptoms associated with advanced disease as well as
the size and location of the more advanced tumors making biopsy access easier. In addition, differences in timeliness to lung cancer diagnosis between early stage and
late stage tumors may have also been affected by a willingness on the part of the clinician or patient to “monitor” the lung nodule and obtain a repeat chest CT after
a specific time interval following the index visit. Nonetheless, depending on tumor stage, some 25–45% of lung
cancer patients exceeded these timing recommendations.
The results from our study suggest that future guidelines
on timeliness and quality of diagnosis should take into
account clinical stage at presentation.
Among those patients with an SPN diagnosis but no
evidence of lung cancer, follow-up procedures, the majority of which were referral visits or additional chest xrays, were performed on the majority of this patient
population. This contrasts with the findings of Pyenson
et al. who studied administrative claims data (i.e., MarketScan) and reported that only 36% received follow-up
care [30]. However, Pyenson and colleagues did not include chest imaging or E&M as part of their algorithm
and these constituted 60–90% of follow-up procedures
in our study. Ideally imaging should be conducted before
the E&M but the data from this study highlight that this
is not always the case. Coding and clinical care are not
that similar and these administrative databses lack the
granularity to address this issue. The use of PET, nonsurgical biopsy and surgical resection as follow-up
measures were quite similar between our study and theirs
(3.4% vs 3.6, 2.9% vs 4.9, 0.4% vs 1% respectively).
The distribution of biopsies among lung cancer
patients in our study mirrored those of others [31–34].
The pattern was slightly different for the SPN cohort in
that approximately 70% of the biopsies were bronchoscopies compared to 48% in the lung cancer cohort. In
addition, the biopsy rate was much lower in the SPN cohort relative to the lung cancer cohort (6% vs 79% respectively). Multiple biopsies were common in both
groups occurring in 25% of the lung cancer group and in
35.5% of the SPN cohort. The frequency of multiple biopsies in the lung cancer cohort was lower in our study
relative to others possibly attributable to the fact that we
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did not include biopsies performed after the diagnosis
date (i.e., for staging purposes) [33–35]. Complications
from biopsy procedures were rare in both patient cohorts with pneumothorax occurring in 4–5% of those
undergoing CT guided biopsy attributable, in part, to the
use of a conservative algorithm to insure an identified
complication was the result of a specific procedure. (see
Appendix 1 for codes).
Currently most lung cancer patients present with advanced disease. Our study is no different in that 69.2%
of patients were diagnosed as stage 3 or 4. As screening
is introduced more widely, the number of small nodules
detected will increase, and most of these will be benign
[36]. Guidelines that use a one-timeline for all can create
counter-productive incentives, leading to unnecessary
biopsies and ignore the value of careful observation and
follow-up of low probability nodules. Guidelines on
timeliness of care should take into account clinical stage
at diagnosis and a more nuanced approach should be
applied. Finally, technological improvements in the
ability to access and biopsy small nodules in peripheral
locations will facilitate more aggressive management of
the SPN without compromising patient safety.
This study is not without limitations. This is a retrospective study that is associated with confounding factors for biopsies and treatment procedures. The patient
population comes from two Louisiana healthcare systems and the patient pathways from nodule identification to diagnosis may not be generalizable to other
healthcare systems throughout the country. However,
findings regarding the stage at diagnosis are consistent
with those previously reported throughout the literature.
In addition, the linking of data from REACHnet with the
Louisiana Tumor Registry resulted in many patients being
excluded from the final cohort per protocol. For example,
almost half of the patients with a diagnosis of lung cancer
in REACHnet were excluded from the final sample
because they had no record in the LTR or no record in
the Tulane or Ochsner healthcare system. The impact of
these patients on the patient pathway results is unknown.

Conclusions
There are significant differences in the timeliness of
diagnosis by cancer stage; stage 3 and 4 cancers being
diagnosed more quickly than stage 1 or 2 cancers. In
addition, there is a great deal of dispersion irrespective
of clinical stage with some 5–20% of patients requiring
more than 6 months to get a diagnosis. These results
suggest that future guidelines on timeliness and quality
of diagnosis should take into account clinical stage at
presentation. More aggressive screening and referral
coupled with timely diagnosis of earlier stage lung
cancer and more aggressive follow-up of SPN will have
the largest impact on patient outcomes.
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